67 citations
,
October 2005 in “Annals of Oncology” This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.
11 citations
,
January 2007 in “Veterinary dermatology” This study found that administerating 10 mg/kg intramuscular fulvestrant did not stimulate hair regrowth in Pomeranian dogs with alopecia X, though higher doses may warrant further investigation.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common side effect of hormone treatments for cancer.